Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
01 Agosto 2023 - 8:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that Derek Maetzold, president and chief executive
officer, is scheduled to present a company overview at the
Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug.
9, 2023, at 12:00 p.m. Eastern time.
A live audio webcast of the Company’s presentation will be
available by visiting Castle Biosciences’ website at
https://ir.castlebiosciences.com/events-presentations/default.aspx.
A replay of the webcast will be available following the conclusion
of the live broadcast.
About Castle Biosciences Castle Biosciences (Nasdaq:
CSTL) is a leading diagnostics company improving health through
innovative tests that guide patient care. The Company aims to
transform disease management by keeping people first: patients,
clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230801292107/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024